Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

N/A

4(57.1%)

Phase 2

2(28.6%)

Early Phase 1

1(14.3%)

7Total

N/A(4)

Phase 2(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05206305Not ApplicableActive Not Recruiting

Sensory-Evoked Cortical Gamma Oscillation

Role: lead

NCT06840028Not ApplicableActive Not Recruiting

Effects of Personalized Exercise Prescriptions Through Mobile Health on Physical Activity and Health Outcomes in the Cancer Survivors

Role: collaborator

NCT05024344Not ApplicableRecruiting

ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy

Role: lead

NCT07393633Completed

Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy

Role: collaborator

NCT06376604Not ApplicableRecruiting

Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies

Role: collaborator

NCT03670160Phase 2Completed

Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome

Role: lead

NCT03710187Phase 2Completed

HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients

Role: lead

NCT03245970Early Phase 1Withdrawn

Impedance Cardiography to Decrease the Risk of Preeclampsia

Role: lead

All 8 trials loaded